SARC001

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

TYPE OF SARCOMA: Ewing’s Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)
DRUG: Imatinib Mesylate (Gleevec)

ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Lee J. Helman, MD
National Cancer Institute (NCI)

CLINICALTRIALS.GOV IDENTIFIER: NCT00031915

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

PUBLICATIONS:
Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH; Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010 Oct 1;16(19):4884-91. doi: 10.1158/1078-0432.CCR-10-1177. Epub 2010 Aug 19. PMID: 20724445.

Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009 Jul 1;27(19):3148-53. doi: 10.1200/JCO.2008.20.5054. Epub 2009 May 18. Erratum in: J Clin Oncol. 2009 Sep 20;27(27):4630. Myers, Paul A [corrected to Meyers, Paul A]. PMID: 19451433.

To learn more about this study or to contact the study research staff: